HLN: Haleon PLC Market Capitalization to Book Value Ratio

Brandmark of Haleon Group (HLN)

The risk for Haleon plc (HLN) remains the probability of sharp drawdowns during shifts in the macroeconomic backdrop, despite a stable cash flow. The market capitalization-to-book ratio demonstrates a support level, where the current figure is 2.00. Resilience is driven by the strong Sensodyne and Theraflu brands, as well as the partial outsourcing of packaging while maintaining in-house production of key products.

Haleon plc (HLN) - Market Capitalization to Book Value Ratio from 04/28/2023 to 10/29/2026
Manufactured product of Haleon PLC

Against a backdrop of geopolitical risks and raw material supply chain disruptions for Haleon plc (HLN), the price-to-book ratio at 2.00 reflects the market's current premium on capital. This indicator compares the company's market value with its net assets, allowing investors to promptly detect overextended valuations relative to the fundamental base and avoid purchasing overpriced securities.

Who Haleon plc competes with

Kenvue Inc. (KVUE) - Market Value to Book Value Ratio|Market Capitalization to Net Assets VRNA (veronapharma.com)|MENS (Jyong Biotech) - Market Capitalization to Book Value Ratio|LGND: Market Value to Book Value|Market Capitalization to Book Value Ratio AMRX|Market Capitalization to Book Value Ratio Perrigo Corp (PRGO)|Market Value to Book Value Ratio Alvotech ALVO|Market Value to Book Value LQDA|GLPG - Market Value to Book Value Ratio|ANI Pharmaceuticals Inc (ANIP) - Market Cap to Net Assets Ratio|MNKD: Market Capitalization to Book Value Ratio|Amphastar Corp (AMPH) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio PCRX|SPRY: Market Value to Book Value|Market Value to Book Value Ratio Theravance Biopharma, Inc. (TBPH)|AQST - Market-to-Book Ratio|scPharmaceuticals - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple TECX (Tectonic Therapeutic Inc.)|Tonix Pharmaceuticals - Market Capitalization to Book Value Ratio|Market Value to Book Value SXTC (China SXT Pharmaceuticals)|EPRX: Market Capitalization to Book Value Ratio|Market-to-Book Ratio BioHarvest Sciences, Inc. (BHST)|Market Value to Book Value Ratio Invizyne Technologies, Inc.|ORMP: Market Value to Book Value|Market Capitalization to Book Value Ratio ENTX|HYFT (ipatherapeutics.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ABVC (ABVC BioPharma, Inc.)|Market Capitalization to Book Value Ratio Cumberland Pharmaceuticals Inc CPIX|QNTM - Market Value to Book Value Ratio|FGEN: Market Value to Book Value Ratio|TELO: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rani Therapeutics Holdings, Inc. (RANI)|Market Value to Book Value Ratio Synergy CHC Corp.|Market-to-Book Ratio Rallybio Corp. RLYB|Market Value to Book Value Ratio Lexaria Bioscience (LEXX)|Pulmatrix Corporation - Capitalization to Book Value Ratio|Pheton Holdings - Market Cap to Net Assets Ratio|Market Value to Book Value APM|LYRA - Market Value to Book Value Ratio|Market Capitalization to Net Assets IBO|tnfpharma.com (TNFA) - Market Value to Book Value Ratio|YCBD (cbdMD) - Market Value to Book Value Ratio|PRFX (PainReform Ltd.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Auris Medical (CYTO)|Market Capitalization to Book Value Ratio LIPO|OPTN (OptiNose Inc) - Market Value to Book Value|Market Value to Book Value Ratio Pieris PIRS|Procaps Group Corp - Market Value to Book Value Ratio|PTPI - Market Value to Book Value Ratio|QLI (qlsyy.net) - Capitalization to Book Value Ratio|ACELYRIN (SLRN) - Market Value to Book Value Ratio|Market Capitalization to Net Assets TFFP (TFF Pharmaceuticals Inc.)